Trends in Fibrosis Research and Drug Discovery: Nonalcoholic Steatohepatitis (NASH)

nash-webinar-the-scientist-2017-700x800.png

What is covered in this webinar:

 

  • Current thinking on NASH etiology and the best approaches for drug-discovery efforts
  • Diagnosing and tracking NASH-induced diseases with noninvasive biomarkers
  • Targeting the Liver X Receptor (LXR) and its promiscuous activities

Speakers

manuela-g-neuman.png

Arun Sanyal, MBBS, PhD -Professor, Departments of Medicine, Physiology, and Molecular Pathology
Virginia Commonwealth University

 

manuela-g-neuman.png

Manuela G. Neuman, MSc, PhD, FCAB -Professor, Department of Pharmacology and Toxicology, University of Toronto. Chief Executive Officer, In Vitro Drug Safety and Biotechnology, Banting Institute

thomas-p-burris.png

Thomas P. Burris, PhD -Professor and Chair,
Department of Pharmacology and Physiology
Saint Louis University School of Medicine

 

Abstract

Many inflammatory disease processes induce fibroblast recruitment, leaving behind fibrosis in their wake; NASH is one such disease. The hallmark of NASH is fat deposition and fibrosis in the liver in the absence of excessive alcohol consumption, and it is closely tied to metabolic dysregulation. 

A panel of experts discuss the industry-wide trends in cell signaling analysis and molecular pharmacology that are informing the search for NASH therapies, explore the challenges of identifying therapeutic targets for multifactorial, lifestyle-induced diseases, and share the latest details of their NASH-directed R&D efforts.

Recorded webinar - The Scientist & Cisbio